U.S. Markets close in 3 hrs 23 mins
  • S&P 500

    4,581.92
    +68.88 (+1.53%)
     
  • Dow 30

    34,658.35
    +636.31 (+1.87%)
     
  • Nasdaq

    15,388.32
    +134.27 (+0.88%)
     
  • Russell 2000

    2,196.27
    +48.85 (+2.28%)
     
  • Crude Oil

    67.10
    +1.53 (+2.33%)
     
  • Gold

    1,764.90
    -19.40 (-1.09%)
     
  • Silver

    22.35
    +0.01 (+0.05%)
     
  • EUR/USD

    1.1305
    -0.0018 (-0.1583%)
     
  • 10-Yr Bond

    1.4600
    +0.0260 (+1.81%)
     
  • Vix

    27.53
    -3.59 (-11.54%)
     
  • GBP/USD

    1.3302
    +0.0024 (+0.1822%)
     
  • USD/JPY

    113.2020
    +0.4220 (+0.3742%)
     
  • BTC-USD

    56,529.50
    -1,944.23 (-3.32%)
     
  • CMC Crypto 200

    1,437.25
    -1.64 (-0.11%)
     
  • FTSE 100

    7,129.21
    -39.47 (-0.55%)
     
  • Nikkei 225

    27,753.37
    -182.25 (-0.65%)
     

AXSM ALERT - Shareholder Rights Firm Labaton Sucharow is Investigating Axsome Therapeutics, Inc. (NASDAQ:AXSM) for Potential Securities Violations and Breach of Fiduciary Duty

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / August 9, 2021 / Labaton Sucharow, a nationally ranked and award-winning shareholder rights firm, is investigating potential securities violations and breach of fiduciary duty claims against Axsome Therapeutics, Inc. (NASDAQ:AXSM).

On August 9, 2021, Axsome Therapeutics, Inc. shares tumbled in response to a disappointing regulatory update for AXS-05 as a potential treatment for major depressive disorder (MDD). Specifically, Axsome revealed during its 2021 second-quarter earnings release that the U.S. Food and Drug Administration (FDA) had notified the company on July 30, 2021 that it has identified deficiencies within the drug's regulatory application that preclude discussion of labeling and post-marketing requirements at this time.

If you currently own stock or options in Axsome Therapeutics, Inc. and want to receive additional information and protect your investments free of charge, please contact David J. Schwartz using the toll-free number (800) 321-0476 or via email at david@labaton.com.

About the Firm

Labaton Sucharow LLP is one of the world's leading complex litigation firms representing clients in securities, antitrust, corporate governance and shareholder rights, and consumer cybersecurity and data privacy litigation. Labaton Sucharow has been recognized for its excellence by the courts and peers, and it is consistently ranked in leading industry publications. Offices are located in New York, NY, Wilmington, DE, and Washington, D.C. More information about Labaton Sucharow is available at Labaton.com.

CONTACT:
David J. Schwartz
(800) 321-0476
david@labaton.com

SOURCE: Labaton Sucharow LLP



View source version on accesswire.com:
https://www.accesswire.com/658961/AXSM-ALERT--Shareholder-Rights-Firm-Labaton-Sucharow-is-Investigating-Axsome-Therapeutics-Inc-NASDAQAXSM-for-Potential-Securities-Violations-and-Breach-of-Fiduciary-Duty